Future OTC Technologies Will Bring Regulatory Challenges – Gottlieb
This article was originally published in The Tan Sheet
Executive Summary
Technological changes in the OTC drug marketplace will prompt changes in the approval process for nonprescription products, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb
Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises
Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb
Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises
Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb
Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises